Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, IDRx
GSK to buy Boston-based IDRx for $1.15 billion
GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement signed by both companies,
GSK confirms plan to buy cancer firm IDRx for $1bn
This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, with another $150 million in payments to the biotech's shareholders if its pipeline delivered as expected.
Drugmaker GSK Buys US Firm Focused On Gastro Cancer
British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specialises in the treatment of rare gastrointestinal cancer GIST.
GSK to buy US biotech firm IDRx for up to $1.15 billion
(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. IDRx,
GSK to buy cancer-focused IDRx in $1 billion deal
LONDON — Seeking to build up its cancer business,
GSK
said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront. The deal, which includes another $150 million in milestone payments, gives
GSK
an experimental treatment for a ...
GSK to acquire IDRx for $1B upfront
GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B
GSK enters agreement to acquire IDRx, Inc.
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.
GSK to buy rare cancer drug developer IDRx for up to £1bn
Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million in 'success-based' milestone payments.
GSK To Acquire GIST Drug Developer IDRx For Up To $1.15 Bln Cash
(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion in cash.
BioSpace
2h
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
FierceBiotech
8h
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
ENDPOINTS NEWS
7h
GSK kicks off JPM dealmaking with $1B+ buyout of IDRx and its rare cancer drug
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
devdiscourse
1h
GSK's Major Biotech Acquisition Highlights Tumour Treatment Innovations
British drugmaker GSK plans to acquire US biotech firm IDRx for $1.15 billion, focusing on innovative tumour treatments.
2d
GSK remains steady Friday, still outperforms market
GSK PLC GSK shares were unchanged Friday at £13.50, on what proved to be an all-around grim trading session for the stock ...
3d
Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease
NEW YORK (PIX11) — A young man, homeless and disheveled, was surrounded by a joint response team made up of two NYPD officers ...
FierceBiotech
3d
GSK-backed Ouro Medicines launches into T-cell engager space with $120M and a clinical-stage asset
Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...
3d
GSK falls Thursday, underperforms market
Shares of GSK PLC GSK inched down 0.77% to £13.50 Thursday, on what proved to be an all-around positive trading session for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
IDRx
United States
RSV
Arexvy
GlaxoSmithKline
Feedback